<p>PureTech Health plc（纳斯达克代码：PRTC - 获取免费报告）在周一的交易中上涨了 2.5%。该股票最高交易价为$18.53，最后交易价为$18.25。在午盘交易中，约有 3,307 股成交，较日均成交量 2,553 股增加了 30%。该股票此前收盘价为$17.80。</p>
<p>获取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>PureTech Health 股票上涨 2.5%</h2>
<p>该公司的 50 日简单移动平均线为$18.55，200 日简单移动平均线为$20.20。</p>
<h2>机构资金流入与流出</h2>
<p>一家对冲基金最近在 PureTech Health 股票中购买了新股份。根据该公司在最近向 SEC 提交的 13F 文件，Millennium Management LLC 在第四季度购买了 PureTech Health plc（纳斯达克代码：PRTC - 免费报告）的新头寸。该公司购买了 45,264 股，价值约为$823,000。截至最近的 SEC 文件，Millennium Management LLC 持有 PureTech Health 的 0.19%。机构投资者持有该公司 0.04% 的股份。</p>
<h2>关于 PureTech Health</h2>
<p>（获取免费报告）</p>
<p>PureTech Health plc 从事生物技术和制药解决方案的开发和商业化，主要在美国。该公司正在开发 LYT-100，目前处于第二阶段，旨在治疗特发性肺纤维化（IPF）；以及 LYT-200，一种 IgG4 单克隆抗体，目前处于 1/2 阶段，针对 galectin-9 用于治疗实体肿瘤和血液恶性肿瘤。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 PureTech Health</li>
<li>如何开始投资便士股票</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求庇护</li>
<li>卖空：如何做空股票</li>
<li>3 只超卖的七只奇迹股票处于关键水平：现在买入吗？</li>
<li>市值计算器：如何计算市值</li>
<li>3M 预计在年中达到$175，且更高的高点很可能出现</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 PureTech Health 吗？</h2>
<p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PureTech Health 并不在名单上。</p>
<p>虽然 PureTech Health 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRTC

<p>PureTech Health（纳斯达克代码：PRTC）股票在交易中上涨了 2.5%，达到 18.25 美元，成交量显著增加。对冲基金 Millennium Management LLC 最近收购了 45,264 股，价值约为 82.3 万美元。该公司专注于开发生物技术解决方案，包括特发性肺纤维化和实体肿瘤的治疗。尽管分析师给予了强烈买入评级，但他们建议还有更好的投资选择</p>

<p>PureTech Health plc (NASDAQ:PRTC - Get Free Report) rose 2.5% during trading on Monday . The stock traded as high as $18.53 and last traded at $18.25. Approximately 3,307 shares traded hands during mid-day trading, an increase of 30% from the average daily volume of 2,553 shares. The stock had previously closed at $17.80.</p>
<div class="lb-trans"><p>PureTech Health plc（纳斯达克代码：PRTC - 获取免费报告）在周一的交易中上涨了 2.5%。该股票最高交易价为$18.53，最后交易价为$18.25。在午盘交易中，约有 3,307 股成交，较日均成交量 2,553 股增加了 30%。该股票此前收盘价为$17.80。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>PureTech Health Stock Up 2.5 %</h2>
<div class="lb-trans"><h2>PureTech Health 股票上涨 2.5%</h2>
</div><p>The firm has a 50 day simple moving average of $18.55 and a 200 day simple moving average of $20.20.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为$18.55，200 日简单移动平均线为$20.20。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A hedge fund recently bought a new stake in PureTech Health stock. Millennium Management LLC bought a new position in PureTech Health plc (NASDAQ:PRTC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned 0.19% of PureTech Health as of its most recent SEC filing. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近在 PureTech Health 股票中购买了新股份。根据该公司在最近向 SEC 提交的 13F 文件，Millennium Management LLC 在第四季度购买了 PureTech Health plc（纳斯达克代码：PRTC - 免费报告）的新头寸。该公司购买了 45,264 股，价值约为$823,000。截至最近的 SEC 文件，Millennium Management LLC 持有 PureTech Health 的 0.19%。机构投资者持有该公司 0.04% 的股份。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>关于 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>PureTech Health plc 从事生物技术和制药解决方案的开发和商业化，主要在美国。该公司正在开发 LYT-100，目前处于第二阶段，旨在治疗特发性肺纤维化（IPF）；以及 LYT-200，一种 IgG4 单克隆抗体，目前处于 1/2 阶段，针对 galectin-9 用于治疗实体肿瘤和血液恶性肿瘤。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
<li>How to start investing in penny stocks</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>Short Selling: How to Short a Stock</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 PureTech Health</li>
<li>如何开始投资便士股票</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求庇护</li>
<li>卖空：如何做空股票</li>
<li>3 只超卖的七只奇迹股票处于关键水平：现在买入吗？</li>
<li>市值计算器：如何计算市值</li>
<li>3M 预计在年中达到$175，且更高的高点很可能出现</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 PureTech Health 吗？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PureTech Health 并不在名单上。</p>
</div><p>While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PureTech Health 目前在分析师中获得了强烈买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PureTech Health (NASDAQ:PRTC) 股价上涨 2.5% - 接下来会发生什么？